



What's New

13.02.2018

NPPA has revised ceiling prices of coronary stents but no changes in classification of coronary stents in Schedule I of DPCO 2013

India's drug pricing regulator has revised the prices of coronary stents bringing one up marginally and cutting another further.

The National Pharmaceuticals Pricing Authority (NPPA) brought up the price of bare metal stents (BES) to Rs. 7,660 from Rs. 7,260 and reduced the price of drug-eluting and biodegradable stents to Rs. 27,890 from Rs. 29,600.

Despite of such revision It seems that all manufacturers/ marketers of Coronary Stents will not be able to increase the prices of bare metal stents (BES) to Rs. 7,660 from Rs. 7,260 as they shall continue to maintain the existing MRP but will have to reduce the price of drug-eluting and biodegradable stents to Rs. 27,890 from Rs. 29,600 as they shall revise the price of all such stents downward not exceeding the ceiling price so revised.

Also NPPA has decided that there is no case for sub classification of DES in the light of lack of enough clinical evidence to support superiority of one DES or other.

Earlier, In February 2017, NPPA, after duly examining in detail and considering all available information/data of coronary stents supply chain and all relevant options for price fixation of Coronary stents, under the prevailing extraordinary circumstances of a failed and exploitative market system characterized by exorbitant, irrational and restrictive trade margins, had decided to fix ceiling prices of Coronary stents, in order to protect public interest which were valid 12th February 2018.

NPPA had invited views and suggestions of all concerned and organised stakeholders' meet for identifying the issues raised by the stakeholders.

Several representations and suggestions both for and against the issues of sub- classification of drug eluting stents (DES), rewarding incremental innovation, an upward revision or no change in the ceiling prices, increase in trade margins and freedom to withdraw unviable brands from indian market were placed before the Authority during its meeting on 5th February 2018 and finally concluded on 12th February 2018.

Authority in its extended meeting held on 12th February 2018 after intensive deliberations on all the issues and available information / market statistics at its disposal, was of the unanimous view that cardiac stents being an essential drug under Schedule I of DPCO 2013 and part of NLEM 2015 having paramount importance on public health needs to continue to be kept under price regulation in larger public interest till the country is under acute and emergent threat of cardiovascular diseases requiring PTC interventions and to prevent the cardiac stents market falling back to its old archaic state characterized by exorbitant margins leading to exploitative pricing, unethical profiteering and extraordinary failed market system causing unwarranted and unreasonable economic burden on out of pocket expenses of helpless patients and their families.

Accordingly, in exercise of the powers delegated by Government of India in the Ministry of Chemicals and Fertilisers under Paragraph 19 of Drugs (Price Control) Order 2013 by S.O.No. 1394

€ dated 30th May 2013, The NPPA having been satisfied in view of extraordinary circumstances and reasons as explained herein above , that it is necessary to do in public interest, hereby fixes and notifies the revised ceiling prices, exclusive of goods and service tax applicable, if any, in respect of Coronary Stents, as specified below:

| Table | | | |
|--------|---|-------------------|------------------------|
| SL.No. | Coronary Stents | Units (In Number) | Ceiling Price (in Rs.) |
| | (Sl. No. 31 in Schedule I of DPCO 2013) | | |
| 1 | 2 | 3 | 4 |
| 1 | Bare Metal Stents | 1 | 7660 |
| 2 | Drug Eluting Stents (DES) which include Metallic DES and Bioresorbable Vascular Scaffold (BVS) / Biodegradable Stents | 1 | 27890 |

The revised ceiling prices shall be applicable from February 13, 2018 and shall be applicable to all stocks of Coronary Stents available for sale in the trade channel and shall be applicable till 31 March 2019 unless revised by another notification.

The revised ceiling prices shall also apply to 'Covered Coronary Stents'.

Also all manufacturers/ marketers of such Coronary Stents having MRP lower than the ceiling prices specified plus goods and service tax as applicable, if any, shall continue to maintain the existing MRP in accordance with Para 13 (2) of the DPCO 2013.

Also all manufacturers/ marketers of such Coronary Stents, selling branded or non-branded of both BMS and DES versions at prices higher than the ceiling price plus goods and service tax as applicable, if any, so fixed and notified by the Government, shall revise the price of all such stents downward not exceeding the ceiling price.

Accordingly to the above conditions, Despite of such revision It seems that all manufacturers/ marketers of Coronary Stents will not be able to increase the prices of bare metal stents (BES) to Rs. 7,660 from Rs. 7,260 as they shall continue to maintain the existing MRP but will have to reduce the price of drug-eluting and biodegradable stents to Rs. 27,890 from Rs. 29,600 as they shall revise the price of all such stents downward not exceeding the ceiling price so revised.

Click the following links for Notifications

[NPPA has revised ceiling prices of coronary stents](#)